FDA Approved: TABRECTA — Original Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved Tabrecta (capmatinib) under Original Application NDA213591 from Novartis for the treatment of adults with metastatic non-small cell lung cancer wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tabrecta (Capmatinib)

Snippet

ORIG AP for TABRECTA (CAPMATINIB)